Ronald Barrett
Director/Board Member at JANUX THERAPEUTICS, INC.
Net worth: - $ as of 2024-05-30
Profile
Ronald W.
Barrett founded XenoPort, Inc. in 1999, where he worked as Chief Executive Officer & Director from 2001 to 2015.
Dr. Barrett also currently works at Janux Therapeutics, Inc., as Director from 2021 and Quadriga BioSciences, Inc., as Director.
Dr. Barrett also formerly worked at Medikine, Inc., as Chairman & Chief Executive Officer from 2017 to 2023, Concert Pharmaceuticals, Inc., as Independent Director from 2014 to 2022, Abbott Laboratories, as Principal in 1989, and Affymax Research Institute, as Senior Vice President-Research from 1989 to 1999.
Dr. Barrett received his undergraduate degree from Bucknell University and doctorate degree from Rutgers State University of New Jersey.
Known holdings in public companies
| Company | Date | Number of shares | Valuation | Valuation date |
|---|---|---|---|---|
JANUX THERAPEUTICS, INC.
-.--% | 2024-02-14 | 0 ( -.--% ) | - $ | 2024-05-30 |
Ronald Barrett active positions
| Companies | Position | Start |
|---|---|---|
| JANUX THERAPEUTICS, INC. | Director/Board Member | 2021-09-06 |
Quadriga BioSciences, Inc.
 Quadriga BioSciences, Inc. Pharmaceuticals: MajorHealth Technology Quadriga BioSciences, Inc. is a privately held pharmaceutical company based in an undisclosed location. The American company is focused on developing proprietary targeted cancer therapies by exploiting the biology of aggressive forms of cancer cells that over-express certain unique amino acid transporters on their cell surfaces. The company's mission is to develop safer and more effective treatments for patients with cancer. The company was founded by Bernd Jandeleit, Kerry J. Koller, and Wolf-Nicolas Fischer. Gordon Ringold has been the CEO of the company since 2015. | Director/Board Member | - |
Former positions of Ronald Barrett
| Companies | Position | End |
|---|---|---|
Medikine, Inc.
 Medikine, Inc. Pharmaceuticals: MajorHealth Technology Medikine, Inc. is a privately held biopharmaceutical company located in an undisclosed location. The American company's mission is to transform the discovery of oncology, autoimmune disorder, and infectious disease therapeutics by employing a versatile drug discovery platform that generates modular "peptikines." These peptikines are peptide mimetics of cytokines that are smaller in molecular size than, and structurally unrelated to, the natural cytokines they emulate. Medikine's lead candidate, mdk-703, is currently in a phase 1 clinical trial in healthy volunteers. Ronald W. Barrett has been the CEO of the company since 2016. | Chief Executive Officer | 2023-06-30 |
| CONCERT PHARMACEUTICALS, INC. | Director/Board Member | 2022-06-08 |
| XENOPORT, INC. | Chief Executive Officer | 2015-09-28 |
Affymax Research Institute
 Affymax Research Institute Miscellaneous Commercial ServicesCommercial Services Part of GSK Plc, Affymax Research Institute is a company that researches and develops pharmaceutical products. The company is based in Palo Alto, CA. Affymax Research Institute was acquired by Affymax, Inc. from GSK Plc on July 30, 2001. | Chief Tech/Sci/R&D Officer | 1998-12-31 |
| ABBOTT LABORATORIES | Corporate Officer/Principal | 1988-12-31 |
Training of Ronald Barrett
| Bucknell University | Undergraduate Degree |
| Rutgers State University of New Jersey | Doctorate Degree |
Experiences
Positions held
Connections
1st degree connections
1st degree companies
Male
Female
Members of the board
Executives
Linked companies
| Listed companies | 2 |
|---|---|
| ABBOTT LABORATORIES | Health Technology |
| JANUX THERAPEUTICS, INC. | Health Technology |
| Private companies | 5 |
|---|---|
Concert Pharmaceuticals, Inc.
 Concert Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Concert Pharmaceuticals, Inc. is a clinical stage biopharmaceutical company, which discovers and develops novel small molecule drugs through the use of deuterium technology. Its product candidates target a range of diseases including autoimmune disorders, inflammation, and central nervous system disorders. The company was founded by Richard H. Aldrich, Roger D. Tung and Christoph H. Westphal on April 12, 2006 and is headquartered in Lexington, MA. | Health Technology |
Affymax Research Institute
Affymax Research Institute Miscellaneous Commercial ServicesCommercial Services Part of GSK Plc, Affymax Research Institute is a company that researches and develops pharmaceutical products. The company is based in Palo Alto, CA. Affymax Research Institute was acquired by Affymax, Inc. from GSK Plc on July 30, 2001. | Commercial Services |
XenoPort, Inc.
 XenoPort, Inc. Pharmaceuticals: MajorHealth Technology XenoPort, Inc. operated as a biopharmaceutical company. Its products included horizant and regnite. The company was founded by Ronald W. Barrett, William J. Dower and Mark A. Gallop on December 17, 1999 and was headquartered in Atlanta, GA. | Health Technology |
Quadriga BioSciences, Inc.
Quadriga BioSciences, Inc. Pharmaceuticals: MajorHealth Technology Quadriga BioSciences, Inc. is a privately held pharmaceutical company based in an undisclosed location. The American company is focused on developing proprietary targeted cancer therapies by exploiting the biology of aggressive forms of cancer cells that over-express certain unique amino acid transporters on their cell surfaces. The company's mission is to develop safer and more effective treatments for patients with cancer. The company was founded by Bernd Jandeleit, Kerry J. Koller, and Wolf-Nicolas Fischer. Gordon Ringold has been the CEO of the company since 2015. | Health Technology |
Medikine, Inc.
Medikine, Inc. Pharmaceuticals: MajorHealth Technology Medikine, Inc. is a privately held biopharmaceutical company located in an undisclosed location. The American company's mission is to transform the discovery of oncology, autoimmune disorder, and infectious disease therapeutics by employing a versatile drug discovery platform that generates modular "peptikines." These peptikines are peptide mimetics of cytokines that are smaller in molecular size than, and structurally unrelated to, the natural cytokines they emulate. Medikine's lead candidate, mdk-703, is currently in a phase 1 clinical trial in healthy volunteers. Ronald W. Barrett has been the CEO of the company since 2016. | Health Technology |
- Stock Market
- Insiders
- Ronald Barrett
